APA Alıntı

Hislop, J., Quayyum, Z., Elders, A., Fraser, C., Jenkinson, D., Mowatt, G., . . . Petty, R. (2011). Clinical effectiveness and cost-effectiveness of imatinib dose escalation for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours that have progressed on treatment at a dose of 400 mg/day: A systematic review and economic evaluation. Health Technol Assess.

Chicago Stili Alıntı

Hislop, J., Z. Quayyum, A. Elders, C. Fraser, D. Jenkinson, G. Mowatt, P. Sharma, L. Vale, ve R. Petty. "Clinical Effectiveness and Cost-effectiveness of Imatinib Dose Escalation for the Treatment of Unresectable And/or Metastatic Gastrointestinal Stromal Tumours That Have Progressed On Treatment At a Dose of 400 Mg/day: A Systematic Review and Economic Evaluation." Health Technol Assess 2011.

MLA Alıntı

Hislop, J., et al. "Clinical Effectiveness and Cost-effectiveness of Imatinib Dose Escalation for the Treatment of Unresectable And/or Metastatic Gastrointestinal Stromal Tumours That Have Progressed On Treatment At a Dose of 400 Mg/day: A Systematic Review and Economic Evaluation." Health Technol Assess 2011.

Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..